Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers

Published:2018-09 Issue: Volume:122 Page:125-133
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Jönsson Martin,Mundin Gill,Sumner Michael

Funder

Mundipharma Research Limited

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference39 articles.

1. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care;Apelt;Pharmacopsychiatry,2013

2. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine–naloxone for heroin dependence;Bell;Addiction,2007

3. Societal costs of prescription opioid abuse, dependence, and misuse in the United States;Birnbaum;Pain Med.,2011

4. Pharmacokinetics of the combination tablet of buprenorphine and naloxone;Chiang;Drug Alcohol Depend.,2003

5. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials;Ciraulo;J. Clin. Pharmacol.,2006

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability;Drug Metabolism and Disposition;2024-05-20

2. Buprenorphine and its formulations: a comprehensive review;Health Psychology Research;2022-08-20

3. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico;Pharmaceutics;2020-12-18

4. Endogenous Opiates and Behavior: 2018;Peptides;2020-10

5. Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence;CNS Drugs;2018-08-16